CDTX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own CDTX shares is 33, representing 51.86% of the company's common stock.

AVEO CAPITAL PARTNERS, LLC, in the last quarter, reduced its stake in CDTX by -100% restricting it's holding to 0 shares of worth nearly -. BANK OF NEW YORK MELLON CORP also lessened -100% of the CDTX shares from its portfolio, reducing its holding to 0 shares of worth -. ALETHEA CAPITAL MANAGEMENT, LLC also shunned CDTX shares holding by -1.79% last quarter which brought its holding to 1.6 million shares worth $1.47M.

As per its latest 13F filing, RENAISSANCE TECHNOLOGIES LLC increased its stake in CDTX by 41.77% in the last quarter. The institutional holder raised its holding to 2.55 million shares having worth more than $2.35M. GEODE CAPITAL MANAGEMENT, LLC also added 4.02% more shares of CDTX to its portfolio, raising its holding to 838.29 thousand shares of worth $771.42K. TOCQUEVILLE ASSET MANAGEMENT L.P. also increased its CDTX shares holding by 71.58% which brought its holding to 163 thousand shares worth $149.96K.

The insider with the most stakes in CDTX is BIOTECH TARGET N V , 10 percent owner at the company. Additionally, CDTX stock is highly held by CFO & CBO Shah Preetam and Chief Operating Officer Daruwala Paul among others.

Company executives, directors, and other insiders own 4.73% percent of Cidara Therapeutics, Inc.'s stock. Within the last six months, there have been 2 transaction(s) in which CDTX insiders have sold stock, totaling 1.83K shares. Insiders that have sold shares include SANDISON TAYLOR, TARI LESLIE, and WARD SHANE.

There have been 0 transaction(s) during the past 6-months in which Cidara Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 40.86K Cidara Therapeutics, Inc. shares are held by insiders, which represents about 4.73% of CDTX stock.

CDTX 10 percent owner, BIOTECH TARGET N V holds the largest portfolio of the company's shares. CDTX shares owned by BIOTECH total nearly 2.3 million.

AVEO CAPITAL PARTNERS, LLC is the largest institutional owner in CDTX which holds 0 shares worth - or 0% of the total CDTX shares outstanding followed by BANK OF NEW YORK MELLON CORP with ownership of 0 shares representing 0% of the CDTX ownership. BVF INC/IL is the third largest stakeholder with 6.86 million shares or 7.6% of the ownership worth more than $6.31M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the CDTX is concerned, it is a stock which is not optionable.

Number of CDTX shares short is 66.98K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 10.95M shares of CDTX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, CDTX has 4.21M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for CDTX is 3.88.